Yumeng Yang

Yuan Zhong, Chenhui Tang, Yumeng Yang et al.

Eye gaze that reveals human observational patterns has increasingly been incorporated into solutions for vision tasks. Despite recent explorations on leveraging gaze to aid deep networks, few studies exploit gaze as an efficient annotation approach for medical image segmentation which typically entails heavy annotating costs. In this paper, we propose to collect dense weak supervision for medical image segmentation with a gaze annotation scheme. To train with gaze, we propose a multi-level framework that trains multiple networks from discriminative human attention, simulated with a set of pseudo-masks derived by applying hierarchical thresholds on gaze heatmaps. Furthermore, to mitigate gaze noise, a cross-level consistency is exploited to regularize overfitting noisy labels, steering models toward clean patterns learned by peer networks. The proposed method is validated on two public medical datasets of polyp and prostate segmentation tasks. We contribute a high-quality gaze dataset entitled GazeMedSeg as an extension to the popular medical segmentation datasets. To the best of our knowledge, this is the first gaze dataset for medical image segmentation. Our experiments demonstrate that gaze annotation outperforms previous label-efficient annotation schemes in terms of both performance and annotation time. Our collected gaze data and code are available at: https://github.com/med-air/GazeMedSeg.

Yumeng Yang, Soumya Jayaraj, Ethan B Ludmir et al.

Automatic identification of clinical trials for which a patient is eligible is complicated by the fact that trial eligibility is stated in natural language. A potential solution to this problem is to employ text classification methods for common types of eligibility criteria. In this study, we focus on seven common exclusion criteria in cancer trials: prior malignancy, human immunodeficiency virus, hepatitis B, hepatitis C, psychiatric illness, drug/substance abuse, and autoimmune illness. Our dataset consists of 764 phase III cancer trials with these exclusions annotated at the trial level. We experiment with common transformer models as well as a new pre-trained clinical trial BERT model. Our results demonstrate the feasibility of automatically classifying common exclusion criteria. Additionally, we demonstrate the value of a pre-trained language model specifically for clinical trials, which yields the highest average performance across all criteria.

Yumeng Yang, Peter Krusche, Kristyn Pantoja et al.

Tables, figures, and listings (TFLs) are essential tools for summarizing clinical trial data. Creation of TFLs for reporting activities is often a time-consuming task encountered routinely during the execution of clinical trials. This study explored the use of large language models (LLMs) to automate the generation of TFLs through prompt engineering and few-shot transfer learning. Using public clinical trial data in ADaM format, our results demonstrated that LLMs can efficiently generate TFLs with prompt instructions, showcasing their potential in this domain. Furthermore, we developed a conservational agent named Clinical Trial TFL Generation Agent: An app that matches user queries to predefined prompts that produce customized programs to generate specific predefined TFLs.

Yumeng Yang, Ashley Gilliam, Ethan B Ludmir et al.

Clinical trials are pivotal in medical research, and NLP can enhance their success, with application in recruitment. This study aims to evaluate the generalizability of eligibility classification across a broad spectrum of clinical trials. Starting with phase 3 cancer trials, annotated with seven eligibility exclusions, then to determine how well models can generalize to non-cancer and non-phase 3 trials. To assess this, we have compiled eligibility criteria data for five types of trials: (1) additional phase 3 cancer trials, (2) phase 1 and 2 cancer trials, (3) heart disease trials, (4) type 2 diabetes trials, and (5) observational trials for any disease, comprising 2,490 annotated eligibility criteria across seven exclusion types. Our results show that models trained on the extensive cancer dataset can effectively handle criteria commonly found in non-cancer trials, such as autoimmune diseases. However, they struggle with criteria disproportionately prevalent in cancer trials, like prior malignancy. We also experiment with few-shot learning, demonstrating that a limited number of disease-specific examples can partially overcome this performance gap. We are releasing this new dataset of annotated eligibility statements to promote the development of cross-disease generalization in clinical trial classification.